Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting a corporate overview at the Biotech Showcase 2019 in San Francisco today at 10:00 am PST.
The presentation will webcast live and the presentation is available for download at the Company’s website: www.bergenbio.com/investors/presentations/
Details for the presentation are as follows:
Date: Tuesday, January 8, 2019
Time: 10:00 am PST
Room: Franciscan A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street
Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.